Selected Publications

Chen X.†, Mao Z.†, Kolawole E.M., Jude K.M., Ogishi M., Mo K.C., McLaughlin J., Cheng  D., Xiang X., Yang X., Gee C., Liu S., Yang A., Obenaus M., Noguchi M., Stoyanova T., Lee J.K., Good Z., Evavold B.D., Witte W.N.*, K. C. Garcia. 2026. Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering. Science. 391: eadx3162

Dhamodaran A., Chen X., Fellmer M., Agrawal D., Danner E., Kuehn R., T. Blankenstein. 2025. Mice with a diverse human T cell receptor repertoire selected on a complete HLA class I haplotype. Nat. Comm. 16(1):5432.

Woodward C.H., Chaudhuri A., Chen X., White W.L., Garcia K.C., Baker D., Sgourakis N.G. 2025. Solution mapping of MHC-I:TCR interactions using a minimalistic protein system. PNAS. 122(24):e2506016122.

Chen X.†, Leisegang M., Ioannis Gavvovidis I., Pollack SM., Lorenz FKM., Schumacher TN., Daumke O., T Blankenstein. 2024. Generation of effective and specific human TCRs against tumor/testis antigen NY-ESO-1 in mice with humanized T cell recognition system. Front. Immunol., 2024 Dec 24:15:1524629.

Poncette L., Chen X., FK. Lorenz FK, T. Blankenstein. 2019. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression. J. Clin. Invest. 129 (1): 324-335. 

Chen X.†, L. Poncette, and T. Blankenstein. 2017. Human TCR-MHC coevolution after divergence from mice includes increased nontemplate-encoded CDR3 diversity. J. Exp. Med. 214:3417–3433.